<DOC>
	<DOCNO>NCT01493245</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety JNS020QD patient moderate severe chronic pain switch opioid analgesic , well safety efficacy long-term treatment ( 52 week ) switch JNS020QD .</brief_summary>
	<brief_title>A Study JNS020QD Patients With Chronic Pain</brief_title>
	<detailed_description>The primary objective study evaluate efficacy safety JNS020QD patient moderate severe chronic pain switch opioid analgesic . It also evaluate safety efficacy long-term treatment ( 52 week ) switch JNS020QD . The study enroll patient moderate severe chronic pain adequately control regular treatment opioid analgesic agent study drug patient consider appropriate investigate conversion ratio switch JNS020QD opioid analgesic , evaluate efficacy safety study drug . This open-label ( people know identity intervention ) , uncontrolled ( study involve control treatment ) , multicenter study . This study consist Screening period ( 1 2 week ) , Period I ( 3-week titration period+ 1-week maintenance period ) , Period II ( 48 week long-term treatment period ) , taper period ( require , 0 6 week ) , follow-up period ( 1 week ) . JNS020QD transdermal system fentanyl base incorporate directly single layer pressure-sensitive high polymerize adhesive , change day ( every 24 hour ) . JNS020QD available 5 formulation contain fentanyl 0.84 mg , 1.7 mg , 3.4 mg , 5 mg , 6.7 mg per system.. The study drug patch apply breast , abdomen , upper arm , femoral region , etc . exchange daily consecutive 52 week .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Chronic pain require opioid analgesic persist 12 week longer give consent Patients receive follow opioid analgesic stable dose treatment chronic pain 7 day longer give consent ( exclude rescue dose ) : oral codeine phosphate ; oral morphine hydrochloride ; fentanyl transdermal ; combination tablet tramadol hydrochloride acetaminophen ; buprenorphine transdermal patch Patients receive 2 less rescue dos per day 7 day give consent Patients whose mean pain intensity throughout day give consent 45 mm less visual analogue scale ( VAS ) Male female patient surgically sterile , abstinent , practice effective method birth control . Female patient negative pregnancy test result screen . Male patient donate sperm study 3 month receive last dose study drug Other painful condition may interfere efficacy evaluation ( eg bone fracture , rheumatoid arthritis ) Major surgery within 30 day screen , fully recover surgery , plan surgery time study Pain consider mainly psychogenic Uncontrolled/clinically significant arrhythmia Hepatic function disorder fulminant hepatitis hepatic cirrhosis , renal impairment nephritic syndrome , acute chronic renal failure Any condition , opinion investigator , would compromise best interest patient could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Chronic Pain</keyword>
	<keyword>JNS020QD</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>Opioid analgesic</keyword>
</DOC>